title: [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
abstract: The remarkable efficacy of PD-1/PD-L1 and CTLA4 immune checkpoint inhibitors has led to numerous approvals in melanoma, non-small cell lung cancer, kidney cancer and several other cancers. Nevertheless, a response is observed in a variable proportion of patients, emphasizing the need for predictive biomarkers of efficacy of immune checkpoint inhibitors effectiveness. Several predictive biomarkers of efficacy are of interest: companion tests such PD-L1 immunohistochemistry, the mutational load, the immune status of the tumor and its molecular profile. They do not allow a perfect selection of the patients, but standardization procedures for certain techniques are ongoing. Moreover the emergence of new approaches, such as the multiplex in situ techniques and the microbiote analysis, may offer the opportunity to better select patients who really benefit from immunotherapy. The goal of this article is to discuss available and promising predictive biomarkers of efficacy for immunotherapy strategies.
authors.affiliation: UM oncologie thoracique, clinique de pneumologie, pôle thorax et vaisseaux, CHU Grenoble-Alpes, 38700 Grenoble, France.
authors.forename: Michaël
authors.initials: M
authors.lastname: Duruisseaux
authors.affiliation: Service d'anatomie pathologique, CHU de Caen, université de Caen, 14003 Caen, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Lize-Dufranc
authors.affiliation: Service d'anatomie pathologique, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France; Faculté Paris Descartes, Inserm U 970, équipe 10, PARCC, 75006 Paris, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Badoual
authors.affiliation: Service d'anatomie pathologique, CHU de Caen, université de Caen, 14003 Caen, France. Electronic address: bibeau-f@chu-caen.fr.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Bibeau
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D015415:Biomarkers / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D060908:CTLA-4 Antigen / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007249:Inflammation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D053842:Microsatellite Instability; D058990:Molecular Targeted Therapy; D009154:Mutation; D009363:Neoplasm Proteins / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D009369:Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D018579:Patient Selection; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D059016:Tumor Microenvironment; D014412:Tumor Virus Infections / Q000188:drug therapy / Q000276:immunology
chemical_list: D000074322:Antineoplastic Agents, Immunological; D060890:B7-H1 Antigen; D015415:Biomarkers; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
keywords: Biomarqueur prédictif; Charge mutationnelle; Immunohistochemistry; Immunohistochimie; Immunotherapy; Immunothérapie; Mutational load; PD-L1; Predictive biomarkers